Merus NV (NASDAQ:MRUS) has been assigned a consensus recommendation of “Hold” from the seven analysts that are presently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $30.25.

A number of brokerages recently issued reports on MRUS. Royal Bank of Canada cut shares of Merus from an “outperform” rating to a “sector perform” rating and set a $28.00 price objective for the company. in a report on Tuesday, January 2nd. BidaskClub upgraded shares of Merus from a “strong sell” rating to a “sell” rating in a report on Saturday, December 30th. Wedbush restated an “outperform” rating and set a $32.00 price objective on shares of Merus in a report on Friday, January 12th. Finally, Zacks Investment Research upgraded shares of Merus from a “sell” rating to a “hold” rating in a report on Tuesday, November 14th.

Shares of Merus (NASDAQ:MRUS) traded down $0.14 during midday trading on Thursday, reaching $19.73. 34,162 shares of the company were exchanged, compared to its average volume of 53,264. The firm has a market capitalization of $387.35 and a PE ratio of -2.82. Merus has a 52-week low of $13.23 and a 52-week high of $30.78.

An institutional investor recently raised its position in Merus stock. Deutsche Bank AG grew its stake in Merus NV (NASDAQ:MRUS) by 146.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,400 shares of the biotechnology company’s stock after buying an additional 5,588 shares during the quarter. Deutsche Bank AG’s holdings in Merus were worth $182,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.42% of the company’s stock.

WARNING: “Merus NV (MRUS) Receives Average Recommendation of “Hold” from Analysts” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at

Merus Company Profile

Merus NV is a biotechnology company based in the Netherlands. The Company develops differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Biclonics format. Its products inlcude, among others, MCLA-134 that is designed to bind to a combination of two immunomodulatory targets expressed by T cells, as wellas MCLA-145 that is designed to bind to a tumor-associated target with an immunomodulatory target involved in checkpoint inhibition.

Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with's FREE daily email newsletter.